$AMAM News

Last published 2y ago

2y agoAMAM KURA RNACartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of DirectorsBusiness Wire– Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline
2y agoAMAMAmbrx Shareholders Approve Acquisition by Johnson & JohnsonGlobeNewswireSAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., ("Ambrx" or the "Company") (NASDAQ:AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into
2y agoAMAM DOOR CBAY WISHKuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
2y agoAMAM GLT JNPR PGTIKuehn Law Encourages PGTI, AMAM, JNPR, and GLT Investors to Contact Law FirmGlobeNewswireNEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
2y agoAMAM CPE JNPR ROVRKuehn Law Encourages CPE, ROVR, AMAM, and JNPR Investors to Contact Law FirmGlobeNewswireNEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
2y agoAMAM AYX EGLE KRTXKuehn Law Encourages AYX, EGLE, AMAM, and KRTX Investors to Contact Law FirmGlobeNewswireNEW YORK, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
2y agoPFE ADCT JNJ AMAM+4Biotech and pharma companies are betting on a promising class of cancer drugs to drive growthCNBCThe JPMorgan Healthcare Conference was likely just the beginning of another year of heightened interest and investments in ADC cancer drugs.
2y agoAMAM HARP AXNX CPEKuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
2y agoAMAM AMGN ELEV NKTX+1Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030GlobeNewswirePALM BEACH, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to the report titled "Aging in the United States," published by the Population Reference Bureau, "the number of
2y agoAMAM JNJ PFE ABBV+1J&J to acquire cancer drug developer Ambrx Biopharma for $2 billionCNBCThe deal, which was announced on the first day of the annual JPMorgan Healthcare Conference, makes J&J the latest drugmaker to bet on ADCs.
2y agoAMAMAMAM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Ambrx Biopharma to Johnson & JohnsonGlobeNewswireMONSEY, N.Y., Jan. 08, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $28.00 per share in cash pursuant to which Ambrx Biopharma, Inc. (NASDAQ:AMAM)
2y agoAMAMAmbrx Announces Sale to Johnson & JohnsonGlobeNewswireSAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ:AMAM), today announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of
2y agoAMAM JNJJohnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of CancerBusiness WirePortfolio of Clinical and Preclinical Programs, Including Lead Product Candidate ARX517, a Prostate-Specific Membrane Antigen (PSMA)-Targeting Antibody Drug Conjugate (ADC), Strengthens Johnson & Johnson's
2y agoAMAM NBIAmbrx to be Added to the NASDAQ Biotechnology Index (NBI)GlobeNewswireSAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx, (NASDAQ:AMAM), today announced that the Company will be added to the NASDAQ Biotechnology Index (NASDAQ:NBI), effective prior to the market
2y agoAMAMAmbrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate CancerGlobeNewswireCohort 9 Following completion of the 21-day observation period at 3.4 mg/kg (Cohort 9), no dose limiting toxicities (DLTs) or serious adverse events (SAEs) were observed Two patients in Cohort 9 experienced rapid PSA
3y agoAMAMAmbrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved TreatmentsGlobeNewswireNewly published data from the Phase 1 portion of the on-goingPhase 1 / 2 APEX-01 trial provide the following key points: Multiple efficacy endpoints demonstrate consistent and promising anti-cancer activity at
3y agoAMAMAmbrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO CongressGlobeNewswireNewly published abstract regarding dose escalation patients provides key updates including: ≥50% PSA reduction observed across putative therapeutic dose levels ≥2.0 mg/kg – 3 of 3 in Cohort 6 (2.0 mg/kg), 2 of 3 in
3y agoAMAMAmbrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023GlobeNewswireSAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the "Company") (NASDAQ:AMAM), today announced that it will host an in-person key opinion leader (KOL) event during the European Society for
3y agoAMAMAmbrx to Participate in the Cantor Fitzgerald Global Healthcare ConferenceGlobeNewswireMorgan Stanley Fireside Chat Replay Now Available SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the "Company") (NASDAQ:AMAM), today announced that Daniel J. O'Connor, Chief Executive
3y agoAMAMAmbrx to Present at the Baird and Morgan Stanley Global Healthcare ConferencesGlobeNewswireSAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the "Company") (NASDAQ:AMAM), today announced that Daniel J. O'Connor, Chief Executive Officer and President of Ambrx, will present a
3y agoAMAMAmbrx Appoints Renu Vaish, M.Sc., as Chief Regulatory Officer to Lead Regulatory AffairsGlobeNewswireSAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc. ("Ambrx" or the "Company") (NASDAQ:AMAM), today announced the appointment of Renu Vaish, M.Sc., as Chief Regulatory Officer. Ms. Vaish will be
3y agoAMAMAmbrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023GlobeNewswireSAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the "Company") (NASDAQ:AMAM), today announced the acceptance of four abstracts for poster presentation at the European Society for Medical
3y agoAMAMFDA Grants Fast Track Designation for Ambrx's ARX517 for the Treatment of Metastatic Castration-Resistant Prostate CancerGlobeNewswireSAN DIEGO, July 19, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the "Company") (NASDAQ:AMAM), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ambrx's
3y agoAMAMAmbrx Announces Closing of $75 Million Market Priced Registered OfferingGlobeNewswireSAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the "Company") (NASDAQ:AMAM), today announced the closing of its previously announced market-priced registered direct offering of
3y agoAMAMAmbrx Appoints Jared Kelly as General CounselGlobeNewswireSAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ:AMAM), today announced the appointment of Jared Kelly as Senior Vice President, General Counsel and Corporate Secretary. After
3y agoAMAMAmbrx to Present at Multiple Upcoming Investor MeetingsGlobeNewswireSAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the "Company") (NASDAQ:AMAM), today announced that Daniel J. O'Connor, Chief Executive Officer and President of Ambrx, will present a
3y agoAMAMAmbrx Announces $75 Million Market Priced Registered OfferingGlobeNewswireSAN DIEGO, May 24, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the "Company") (NASDAQ:AMAM), today announced that it has entered into a securities purchase agreement with clients managed by Darwin
3y agoAMAMAmbrx Appoints Stephen Glover as Chairman of its Board of DirectorsGlobeNewswireSAN DIEGO, May 18, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ:AMAM), today announced that Stephen Glover has joined the Company's Board of Directors as Chairman. Mr. Glover has extensive experience
3y agoAMAMAmbrx to Present at JMP Securities Life Sciences and RBC Capital Markets Global Healthcare ConferencesGlobeNewswireSAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ:AMAM), today announced that Daniel J. O'Connor, Chief Executive Officer and President of Ambrx, will present a corporate overview at
3y agoAMAMAmbrx Expands Leadership Team with Appointment of Andrew Aromando as Chief Operating OfficerGlobeNewswireSAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ:AMAM), today announced the appointment of Andrew P. Aromando as Chief Operating Officer. Mr. Aromando brings over 30 years of
3y agoAMAMAmbrx Presents New Preclinical Data on ARX517 and ARX305 at the 2023 AACR Annual MeetingGlobeNewswireSAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ:AMAM), announced new preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida,
3y agoAMAMAmbrx to Present Preclinical Data on ARX517 and ARX305 at the 2023 AACR Annual MeetingGlobeNewswireSAN DIEGO, March 27, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ:AMAM), announced the presentation of three posters featuring preclinical data at the upcoming 2023 American Association for Cancer
3y agoAMAMAmbrx Raises $78 Million and Completes its ATM ProgramBusiness WireAmbrx Biopharma Inc., or Ambrx (NYSE:AMAM), today announced that it has completed net sales of approximately $78 million of American Depositary Shares ("ADSs") pursuant to the Company's at-the-market ("ATM") program
3y agoAMAMAmbrx to Commence Trading on NasdaqBusiness WireCompany to Transfer Stock Exchange Listing from NYSE to Nasdaq Ticker symbol will remain "AMAM" Ambrx Biopharma Inc. (NYSE: AMAM) ("Ambrx" or "the Company") today announced that it will voluntarily transfer its stock
3y agoAMAMACE-Breast-02 Pivotal Phase 3 Study of Ambrx's ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive ResultsBusiness WireInterim analysis of the ACE-Breast-02 study being conducted by Ambrx's partner, NovoCodex Biopharmaceuticals, was completed by the Independent Data Monitoring Committee (IDMC) The pivotal Phase 3 ACE-Breast-02 study
3y agoAMAM ATNM AZN BMY+1Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029PR NewswireFinancialNewsMedia.com News Commentary PALM BEACH, Fla., Feb. 22, 2023 /PRNewswire/ -- Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children. Leukemia is a type of
3y agoAMAMARX517, Ambrx's Proprietary Anti-PSMA ADC, Shows Encouraging Single-Agent Safety and Efficacy Data in Patients with Advanced Prostate CancerBusiness WireFirst clinical data from ongoing Phase 1 dose escalation trial (APEX-01) shows a prostate-specific antigen (PSA) decrease of > 50% reduction in PSA levels from baseline in 3 of 3 patients with metastatic prostate
3y agoAMAMAmbrx Biopharma to Host Analyst and Investor Day to Discuss ARX788 in Breast Cancer and ARX517 in Prostate CancerBusiness WireVirtual presentation to take place on February 24, 2023 at 12:00pm ET Event will feature discussions regarding ARX788, Ambrx's proprietary anti-HER2 targeting ADC, from key opinion leaders in breast cancer, Hope S.
3y agoAMAMAmbrx Biopharma Strengthens Clinical Leadership with Appointment of Sandra Aung, Ph.D. as Head of Clinical DevelopmentBusiness WireAmbrx Biopharma, Inc., or Ambrx (NYSE:AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create antibody-drug conjugates (ADCs), has appointed
3y agoAMAMAmbrx Biopharma Inc. Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading PriceBusiness WireAmbrx Biopharma Inc. (Ambrx) (NYSE:AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics platform to create antibody drug conjugates, announced today that it received
3y agoAMAMAmbrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 TreatmentBusiness WireData to be discussed in a Spotlight Poster Presentation at the 2022 San Antonio Breast Cancer Symposium Preliminary Phase 2 results from ACE-Breast-03 study demonstrate 57.1% confirmed overall response rate (ORR) by
3y agoAMAMInterim Data from Ambrx's Study of ARX788 selected for Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer SymposiumGlobeNewswireSAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create
4y agoAMAMAmbrx Announces NovoCodex's Dosing of First Patient with ARX305, Ambrx's Investigational Antibody Drug Conjugate Targeting CD70Business Wire- ARX305 is being evaluated by Ambrx's partner, NovoCodex, in a Phase 1 clinical trial in various advanced tumors - - First patient dosing triggers milestone payment to Ambrx - - NovoCodex responsible for funding
4y agoAMAMAmbrx Biopharma Inc. Appoints Daniel O'Connor as Chief Executive OfficerBusiness WireAmbrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the
4y agoAMAMAmbrx Biopharma Inc. Announces Strategic Reprioritization and Provides Corporate UpdateGlobeNewswire- Company now focused on earlier stage engineered antibody drugs for cancer therapies, including new lead asset ARX517 – - Revised focus and projected cost-reductions expected to extend cash runway into 2025 – - Ambrx
4y agoAMAMAmbrx Biopharma to Host Corporate Update Conference CallGlobeNewswireSAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision
4y agoAMAMAmbrx Biopharma Inc. Reports 1H 2022 Financial Results and Provides Corporate UpdateBusiness Wire- Appointed Kate Hermans as Interim Chief Executive Officer – Ambrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EP
4y agoAMAMAmbrx Biopharma Appoints Kate Hermans as Interim CEO, Replacing Feng TianBusiness Wire- Katrin Rupalla, Ph.D., appointed Chair of Ambrx's Board of Directors - - Ambrx to conduct strategic pipeline review with focus on commercial opportunity and cash runway extension - - Dr. Tian will continue to be available to Ambrx in an advisory
4y agoAMAMAmbrx Biopharma Appoints Edward Hu and Kate Hermans to its Board of DirectorsBusiness WireAmbrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointments of Edward Hu and Kate Hermans
4y agoAMAMAmbrx Biopharma Inc. to Present at the H.C. Wainwright Preclinical Cancer Drug Discover ConferenceBusiness WireAmbrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced that Feng Tian, Ph.D., Chairman of the Board, Pre